Country: Canada
Language: English
Source: Health Canada
HYDROXYCHLOROQUINE SULFATE
SANIS HEALTH INC
P01BA02
HYDROXYCHLOROQUINE
200MG
TABLET
HYDROXYCHLOROQUINE SULFATE 200MG
ORAL
15G/50G
Prescription
ANTIMALARIALS
Active ingredient group (AIG) number: 0107403001; AHFS:
APPROVED
2021-08-26
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR HYDROXYCHLOROQUINE Hydroxychloroquine Sulfate Tablets Tablets, 200 mg, Oral USP Anti-Inflammatory – Antimalarial – Aminoquinolines Sanis Health Inc. 1 President's Choice Circle Brampton, Ontario L6Y 5S5 Date of Initial Authorization: AUG 26, 2021 Date of Revision: JUL 19, 2023 Submission Control Number: 276674 _HYDROXYCHLOROQUINE (hydroxychloroquine sulfate tablets _ _Page 2 of 43 _ _ _ RECENT MAJOR LABEL CHANGES 2 Contraindications 08/2021 4 Dosage and Administration, Pregnant Women 02/2022 7 Warnings and Precautions, Hematologic 02/2022 7 Warnings and Precautions, Musculoskeletal 02/2022 7 Warnings and Precautions, Psychiatric 02/2022 7 Warnings and Precautions, Skin 03/2023 7 Warnings and Precautions, 7.1.1 Pregnant Women 02/2022 7 Warnings and Precautions, 7.1.4 Geriatrics 02/2022 7 Warning and Precautions, Cardiovascular 07/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ................................................................................................................... 4 1.2 Geriatrics ................................................................................................................... 4 CONTRAINDICATIONS ................................................................................................. 5 DOSAGE AND ADMINISTRATION ................................................................................. 5 4.1 Dosing Considerations: ................ Read the complete document